Dataset Information


Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

ABSTRACT: Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (Fc?Rs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NF?B promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies. Mol Cancer Ther; 17(5); 1024-38. ©2018 AACR.


PROVIDER: S-EPMC5932227 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6299665 | BioStudies
2012-01-01 | S-EPMC3449097 | BioStudies
2015-01-01 | S-EPMC4621427 | BioStudies
2020-01-01 | S-EPMC7847261 | BioStudies
2017-01-01 | S-EPMC5333968 | BioStudies
2010-01-01 | S-EPMC3058673 | BioStudies
2016-01-01 | S-EPMC6536381 | BioStudies
1000-01-01 | S-EPMC3926072 | BioStudies
2018-01-01 | S-EPMC6338386 | BioStudies
2008-01-01 | S-EPMC3705866 | BioStudies